Pipelines Of Generic Drug Firms May Become More Transparent Under FDAAA
Executive Summary
Generic drug firms may soon be forced to disclose their bioequivalence trials under a provision of the FDA Amendments Act that requires companies to post clinical studies on a public Web site.
You may also be interested in...
FDA Ponders Whether To Publicly Discuss Pending NDAs And INDs; Should Agency Reply To Studies Published In Journals?
FDA leadership is considering whether, and to what extent, the agency should be able to publicly discuss INDs, drug applications and complete response letters
FDA Ponders Whether To Publicly Discuss Pending NDAs And INDs; Should Agency Reply To Studies Published In Journals?
FDA leadership is considering whether, and to what extent, the agency should be able to publicly discuss INDs, drug applications and complete response letters
NIH Trials Registry Growing Quickly; Global Standards Up For Discussion
The federal clinical trials registry is growing at a 20 to 40 percent faster clip as a result of the FDA Amendments Act provision expanding the universe of trials subject to public listing requirements